A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review

Abdelmogod, A; Papadopoulos, L; Riordan, S; Wong, M; Weltman, M; Lim, R; McEvoy, C; Fellowes, A; Fox, S; Bedo, J; Penington, J; Pham, K; Hofmann, O; Vissers, JHA; Grimmond, S; Ratnayake, G; Christie, M; Mitchell, C; Murray, WK; McClymont, K; Luk, P; Papenfuss, AT; Kee, D; Scott, CL; Goldstein, D; Barker, HE

Author(s): Abdelmogod, A; Papadopoulos, L; Riordan, S; Wong, M; Weltman, M; Lim, R; McEvoy, C; Fellowes, A; Fox, S; Bedo, J; Penington, J; Pham, K; Hofmann, O; Vissers, JHA; Grimmond, S; Ratnayake, G; Christie, M; Mitchell, C; Murray, WK; McClymont, K; Luk, P; Papenfuss, AT; Kee, D; Scott, CL; Goldstein, D; Barker, HE;
Details: Publication Year 2023-09-01,Volume 15,Issue #17,Page 4378
Journal Title: Cancers
Publication Type: Research article
Abstract: BACKGROUND: Epithelioid haemangioendothelioma (EHE) is an ultra-rare malignant vascular tumour with a prevalence of 1 per 1,000,000. It is typically molecularly characterised by a WWTR1::CAMTA1 gene fusion in approximately 90% of cases, or a YAP1::TFE3 gene fusion in approximately 10% of cases. EHE cases are typically refractory to therapies, and no anticancer agents are reimbursed for EHE in Australia. METHODS: We report a cohort of nine EHE cases with comprehensive histologic and molecular profiling from the Walter and Eliza Hall Institute of Medical Research Stafford Fox Rare Cancer Program (WEHI-SFRCP) collated via nation-wide referral to the Australian Rare Cancer (ARC) Portal. The diagnoses of EHE were confirmed by histopathological and immunohistochemical (IHC) examination. Molecular profiling was performed using the TruSight Oncology 500 assay, the TruSight RNA fusion panel, whole genome sequencing (WGS), or whole exome sequencing (WES). RESULTS: Molecular analysis of RNA, DNA or both was possible in seven of nine cases. The WWTR1::CAMTA1 fusion was identified in five cases. The YAP1::TFE3 fusion was identified in one case, demonstrating unique morphology compared to cases with the more common WWTR1::CAMTA1 fusion. All tumours expressed typical endothelial markers CD31, ERG, and CD34 and were negative for pan-cytokeratin. Cases with a WWTR1::CAMTA1 fusion displayed high expression of CAMTA1 and the single case with a YAP1::TFE3 fusion displayed high expression of TFE3. Survival was highly variable and unrelated to molecular profile. CONCLUSIONS: This cohort of EHE cases provides molecular and histopathological characterisation and matching clinical information that emphasises the molecular patterns and variable clinical outcomes and adds to our knowledge of this ultra-rare cancer. Such information from multiple studies will advance our understanding, potentially improving treatment options.
Publisher: MDPI
Keywords: ARC Portal; Sfrcp; Taz; Yap; biomarker; epithelioid haemangioendothelioma; fusion genes; genomics; histopathology; rare cancer
Department(s): Pathology; Medical Oncology; Laboratory Research
PubMed ID: 37686662
Publisher's Version: https://doi.org/10.3390/cancers15174378
Open Access at Publisher's Site: https://doi.org/10.3390/cancers15174378
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-11-14 12:57:55

Last Modified: 2023-11-14 12:58:13